Tumor stem cell-derived exosomal microRNA-17-5p inhibits anti-tumor immunity in colorectal cancer via targeting SPOP and overexpressing PD-L1

Wei Sun1, Junpeng Cui1, Yang Ge1, Jinshi Wang1, Yifan Yu1, Bing Han1 and Baolin Liu1✉

© The Author(s) 2022

Exosomes are known to transmit microRNAs (miRNAs) to affect human cancer progression, and miR-17-5p has been manifested to exert facilitated effects on colorectal cancer (CRC) progression, while the role of tumor stem cells-derived exosomal miR-17-5p in CRC remains unknown. We aim to explore the effect of CRC stem cells-derived exosomes (CRCSC-exos) conveying miR-17-5p on CRC. The exosomes were isolated from CRC stem cells and identified. HCT116 cells were transfected with speckle-type POZ protein (SPOP) interfering vector or co-cultured with exosomes carrying miR-17-5p mimic/inhibitor. Then, the proliferation, migration, invasion, and apoptosis of the cells were determined. The xenograft mouse model was constructed using BALB/C mice and the serum levels of T cell cytokines were assessed. Expression of miR-17-5p, SPOP, CD4, CD8 and programmed death ligand 1 (PD-L1) was detected. The targeting relationship between miR-17-5p and SPOP was verified. MiR-17-5p was upregulated and SPOP was downregulated in CRC tissues. CRCSC-exos transmitted miR-17-5p to HCT116 cells to promote malignant behaviors and suppress anti-tumor immunity of HCT116 cells. The overexpressed SPOP exerted opposite effects. SPOP was concreted as a target gene of miR-17-5p. Upregulated CRCSC-exosomal miR-17-5p inhibits SPOP to promote tumor cell growth and dampen anti-tumor immunity in CRC through promoting PD-L1.

Cell Death Discovery (2022) 8:223 ; https://doi.org/10.1038/s41420-022-00919-4

INTRODUCTION
Colorectal cancer (CRC) kills almost 700,000 people every year, ranking the top four (after lung, liver, and stomach cancer) for inducing cancer-related death globally [1, 2]. CRC is a complex process featured by multiple genomic variations and the abnormal biological microenvironment [3]. About 55% of CRC cases happened in developed countries, indicating that it is more prevalent in developed regions [4]. The underlying mechanisms of CRC are multifactorial and the risk factors of CRC contain gender, age, and lifestyle, with underlying genetics significant to a lesser extent [5]. Although addressability, awareness, and screening have been developed, there remains 25% of the cases diagnosed as CRC at advanced stages [6]. Nowadays, CRC patients are treated with surgical resection, chemotherapeutic drugs, or adjuvant. These therapeutic strategies improved the overall survival rate of CRC patients. Nevertheless, the treatments were accompanied by severe side effects, such as weight loss, vomiting, nausea, and risk of infectious complications [7]. Thus, developing more effective strategies for the treatment of CRC is vital.

Exosomes are vesicles with ~100–150 nm in diameter and released from several mammalian cell types. Exosomes can dock and fuse to the target cell membrane, transmitting exosomal surface proteins and cytoplasm. Thus, exosomes were usually used as delivery vehicles for microRNAs (miRNAs) as exosomes do not induce adverse immune responses and have a low risk for tumorigenesis [8]. miRNAs are a type of small and single-stranded RNA with ~22 nt in length and lack protein-coding ability. miRNAs can regulate gene expression at a post-translational level by binding to the 3’-untranslated region (UTR) of target mRNAs, resulting in mRNA degradation or translation inhibition [9]. It has been reported that miR-96 promoted the occurrence and progression of CRC [10], and a study has revealed that the elevation of miR-224 promoted CRC cell migration and invasion [11]. The miR-17-5p–92 cluster was initially described as an oncogene cluster and identified to drive vital physiological responses during disease development [12]. In this cluster, miR-17-5p is specifically oncogenic and usually upregulated in human cancers [13, 14]. For instance, in the non-invasive measurement of CRC, circulating miR-17-5p is available to serve as an early biomarker in CRC [15]. MiR-17-5p has also been manifested to exert facilitated effects on CRC progression [16]. Specifically, the cancer-associated fibroblast (CAF)-derived exosomal miR-17-5p promoted CRC malignant phenotypes [17]. Furthermore, high-expressed exosomal miR-17-5p is implicated in pathological stages and grades of CRC patients [18]. These discoveries unraveled the great potential of miR-17-5p in CRC development. As for the programmed death ligand 1 (PD-L1), it has been validated that the administration of anti-PD-L1 contributes to dampening the growth of tumor cells in normal syngeneic mice, suggesting that the PD-L1 serves as an effective modulator for potentially immunogenic tumors to escape from the host immune responses [19]. Relatively, Audrito et al. have elucidated that...
plasmatic miR-17-5p levels were elevated in metastatic melanoma patients with PD-L1+,[23] validating the marker role of miR-17-5p to PD-L1 expression [20]. In our study, bioinformatics analysis revealed that miR-17-5p had binding sites with Speckle-type POZ (SPOP). SPOP is an E3 ubiquitin ligase adapter that can serve as a tumor suppressor [21]. It has been revealed that silencing SPOP by promoter hypermethylation decreased cell apoptosis in CRC[22], and SPOP has been identified to play a critical role in CRC through mesenchymal–epithelial transition and matrix metalloproteinases[23].

As stated above, miR-17-5p from tumor-derived cells acted as a promising modulator for cancer development and the survival of cancer patients, indicating its potential therapeutic value in cancer treatment; while the detailed function of exosomal miR-17-5p from tumor-derived cells in CRC progression remained obscure. Considering such conditions, we designed the study to explore the function of the CRCSC-derived exosomes (CRCSC-exos) conveying miR-17-5p in CRC development with the involvement of SPOP, and we further speculate that CRCSC-derived exosomal miR-17-5p may target SPOP to regulate the CRC cell growth.

RESULTS
CRC stem cell sorting and exosome identification
Surface markers CD133 and CD44 were broadly used to select and isolate the CRC stem cells from CRC cells [24]. In this study, the subpopulation of CD133+CD44+ accounted for <1.00% in HCT116 cells before the experiment. After incubated in SFM, the ratio of CD133+CD44+ cells was increased, and these cells were CRC stem cells (Fig. 1A).

As observed through a TEM, the exosomes derived from CD133+CD44+ HCT116 cells had a membranous morphology (Fig. 1B). Results of NTA implied that exosome diameter ranged from 50 to 300 nm (Fig. 1C). The expression of exosome markers (HSP70 and CD81) could be observed in the exosomes (Fig. 1D). The exosome uptake experiment revealed that the fluorescent PKH26-labeled exosomes successfully entered HCT116 cells. To further explore the transmission of miR-17-5p, we electrotransferred FITC-miR-17-5p (green) into CRCSC, extracted cellular exosomes, added Dil tags (red), and incubated HCT116 cells for 48 h. Co-localization of FITC and Dil was observed in recipient cells, indicating that the FITC-miR-17-5p-containing cellular exosomes were internalized by cells (Fig. 1E). miR-17-5p was upregulated in exosomes after the CD133+CD44+ HCT116 cells were introduced with miR-17-5p mimic, and miR-17-5p expression was also increased in HCT116 cells after the cells were co-cultured with exosomes conveying miR-17-5p mimic (Fig. 1F). The results indicated the successful isolation of CRCSC-exos.

CRCSC-exos promote malignancy of HCT116 cells
As previously reported, the CAF-derived exosomes promoted CRC metastasis [17]. Thus, we speculated that CRCSC-exos may facilitate CRC progression.

The proliferation was assessed using colony formation assay and CCK-8 assay; apoptosis was determined using flow cytometry; invasion and migration were assessed through Transwell assay. The results of these experiments (Fig. 2A–D) showed that the CRCSC-exos promoted proliferation, migration, and invasion and inhibited apoptosis of HCT116 cells, revealing the oncogenic role of CRCSC-exos in CRC.

CRCSC-exos reduce anti-tumor immunity in CRC
Generally, the immune system can identify and remove tumor cells in the tumor microenvironment. Nevertheless, tumor cells can affect the expression of T cell cytokines to inhibit the immune system, thus the tumor cell killing was suppressed [25]. It has been reported that PTPN2 deficiency in T cells enhances the efficacy of cancer immuno-monitoring and over-metastatic tumor-specific T cells. T cell-specific PTPN2 deficiency also prevents tumor formation in elderly mice, and tumor suppressor p53 was heterozygous. CD8+ T cells with metastatic PTPN2 defect saliently inhibits the formation of mammary tumor in mice. PTPN2 is a target for enhancing T cell-mediated anti-tumor immunity and CAR-T cell therapy of solid tumors [26]. Such discoveries reflected that the tumor immune microenvironment affected the occurrence and development of tumors, and provided novel insights for tumor treatment.

Here we further explored the effect of CRCSC-exos on the tumor microenvironment by establishing a xenograft mouse model. The results implied that the treatment of CRCSC-exos promoted the tumor volume and weight (Fig. 3A). Serum of experimental mice was collected 72 h after exocrine injection, T cell cytokine contents in mouse serum were determined and it was found that the exosomes reduced tumor necrosis factor-α (TNF-α) and interleukin (IL)-2 contents while increasing IL-10 and transforming growth factor-β (TGF-β) contents in enzyme-linked immunosorbent assay (ELISA; Fig. 3B–E). Moreover, the results of HE staining reflected that the inflammatory infiltration of tumor tissue was promoted after exosome treatment; while the immunohistochemical staining of the tumor section showed that, after exosome treatment, CD4+ and CD8+ T cell infiltration was alleviated (Fig. 3F).

CRCSC-exos upregulating miR-17-5p facilitates malignant behaviors of HCT116 cells
MiR-17-5p participates in CRC progression [17, 27]. Thus, we detected miR-17-5p expression in clinical samples. Our results suggested that miR-17-5p was upregulated in CRC tissues (Fig. 4A).

HCT116 cells were treated with CRCSC-exos transmitting miR-17-5p mimic/inhibitor to explore the role of exosomal miR-17-5p in CRC cell processes. These findings in our experiments reflected that compared to HCT116 cells co-cultured with miR-17-5p-NC-Exo, the exosomal miR-17-5p facilitated proliferation, migration and invasion, and restricted apoptosis of HCT116 cells, while those miR-17-5p inhibitor-Ex treatment exerted opposite effects on HCT116 cells (Fig. 4B–E), indicating the promotive role of upregulated exosomal miR-17-5p in CRC cell growth.

CRCSC-exos upregulating miR-17-5p suppresses anti-tumor immunity in CRC
To unravel the impacts of miR-17-5p on anti-tumor immunity in CRC, the xenograft modeled mice were treated with CRCSC-exos elevating or inhibiting miR-17-5p to reveal the role of exosomal miR-17-5p in anti-tumor immunity in CRC, and tumor samples and mouse serum were tested. The results showed that compared to miR-17-5p-NC-Exo-treated nude mice, CRCSC-exos upregulating miR-17-5p treatment increased tumor volume and weight, reduced serum contents of TNF-α and IL-2, and relieved the CD4+ and CD8+ T cell infiltration, yet facilitated the inflammatory infiltration and promoted serum contents of IL-10 and TGF-β; the exosomes silencing miR-17-5p treatment exerted contrary effects (Fig. 5A–F). These findings suggested that CRCSC-exos upregulating miR-17-5p deteriorated CRC, promoted tumor growth, and repressed the anti-tumor immunity of CRC.

MiR-17-5p targets SPOP
SPOP expression was detected in clinical samples and we found that it was downregulated in CRC (Fig. 6A, B). The result of the Pearson test indicated a negative relationship between the expression of miR-17-5p and SPOP in CRC samples (Fig. 6C). Thus, we speculated that miR-17-5p may target SPOP.

It was predicted at a bioinformatic website that there existed binding sites between miR-17-5p and SPOP (Fig. 6D). The dual-luciferase reporter gene assay further revealed that the co-transfection of SPOP-wt and miR-17-5p mimic suppressed the luciferase activity (Fig. 6E). Moreover, results of RIP assay showed that miR-17-5p and SPOP expression was enriched in Ago2
The results of RT-qPCR and Western blot analysis implied that SPOP was downregulated (upregulated) after miR-17-5p expression was increased (decreased) (Fig. 6G). These findings indicated the targeting relationship between miR-17-5p and SPOP.

**SPOP overexpression inhibits biological functions of HCT116 cells**

HCT116 cells were transfected with pcDNA-SPOP to alter SPOP expression, and we found that SPOP expression was successfully increased after the transfection (Fig. 7A, B). Then, the biological
functions of transfected HCT116 cells were determined through a series of assays. It was discovered that overexpressed SPOP hindered proliferation, migration, and invasion and promoted apoptosis of HCT116 cells (Fig. 7C–F). Thus, it could be concluded that SPOP upregulation inhibited CRC cell growth.

**MiR-17-5p targets SPOP to upregulate PD-L1, thus affecting the anti-tumor immunity in CRC cells**

Immune checkpoint mediated by PD-1 and its ligand PD-L1 has been approved to be used for human cancer treatment, and it has been revealed that SPOP deletion could block the ubiquitin-induced PD-L1 degradation to increase PD-L1 protein expression [28].

We detected PD-L1 protein expression in HCT116 cells and found that miR-17-5p inhibited SPOP to upregulate PD-L1 (Fig. 8A, B). Immunohistochemical staining detection of SPOP and PD-L1 levels in xenograft tumors showed that miR-17-5p elevated PD-L1 expression by suppressing SPOP expression (Fig. 8C).

**DISCUSSION**

CRC is one of the most dangerous cancers and its global incidence and mortality have increased markedly over the past decades. Though genetic and epigenetic changes of CRC have been broadly reported, the molecular mechanisms in the development of CRC remain to be further explored [29]. We aim to investigate the role of CRCSC-derived exosomal miR-17-5p during CRC development with the involvement of SPOP. Our experimental results revealed that CRCSCs-exos upregulated miR-17-5p, which targeted SPOP to promote growth and inhibit anti-tumor immunity in CRC cells through promoting PD-L1.

The effect of exosomes on CRC progression has been reported before. For instance, CAFs-derived exosomes have been validated to promote metastasis and chemotherapy resistance in CRC [30], and Cheng et al. have demonstrated that the stem-like tumor exosomes promote tumorigenesis and are associated with an immune-suppressive tumor microenvironment in CRC [31]. In the present study, the CRC cells were transfected with CRCSC-exos to observe the role of the exosomes in CRC cell growth. Our results indicated that the CRCSC-exos promoted proliferation, migration, and invasion and inhibited apoptosis of CRC cells. Moreover, the findings in our in vivo assay suggested that the CRCSC-exos suppressed the tumor growth and anti-tumor immunity in CRC. Similarly, research has uncovered that the exosomes from SW480 CRC cells facilitate the migration of HepG2 hepatocellular cancer cells [32]. Another study has revealed that the increased secretion of CRCSC-exos was accompanied by elevated tumor infiltration of myeloperoxidase neutrophils, which promotes tumorigenesis of CRC cells via IL-1β [24]. These data provided a theoretical basis for identifying the role of CRCSC-exos during CRC development. Additionally, the miRNAs can be secreted into the extracellular space, mostly in the form of exosomes, and function in intercellular communication [8]. It has been suggested that the CRCSC-derived exosomal miR-146a-5p promoted stem-like properties and tumorigenicity in recipient CRC cells [31], indicating the involvement of CRCSC-derived exosomal miRNA in CRC progression. As previously reported, the miR-17-92 cluster shows higher expression in CRC tissues, and only miR-17-5p is differentially expressed among adjacent, adenoma, and CRC tissues among the three miRNAs [33]. Moreover, Ma et al. have reported the oncogenic role of miR-17-5p, which is upregulated in CRC tissues and this high expression of miR-17-5p indicates a shorter overall survival rate [16]. Here we detected miR-17-5p expression in clinical samples, and it was found that miR-17-5p was upregulated in CRC tissues versus the adjacent normal tissues. It has been revealed that the CAFs-derived exosomal miR-17-5p promotes the metastasis and progression of CRC [17]. Thus, we speculated that exosomal miR-17-5p may contribute to CRC development. The CRC cells were co-cultured with CRCSC-exos delivering miR-17-5p mimic or inhibitor to verify the role of exosomal miR-17-5p in CRC, and we observed that CRCSC-exos upregulating miR-17-5p facilitated proliferation, migration and invasion, and restricted apoptosis of CRC cells, and also inhibited tumor growth as well as anti-tumor immunity in CRC. Oppositely, CRCSC-exos downregulating miR-17-5p had reverse effects. In addition, we have confirmed the targeting relationship between miR-17-5p and SPOP in CRC cells using bioinformatic prediction and luciferase assay. It is a novel finding that was scarcely explored before. We also detected SPOP expression and it was discovered that SPOP expression was decreased in CRC tissues. Similarly, Xu et al. have reported the frequent SPOP downregulation in CRC tissues and indicates poor differentiation status of CRC [34]. The expression of SPOP was regulated in our experiments to identify the role of SPOP in the biological processes of CRC cells. The results in our study suggested that the overexpression of SPOP inhibited malignant behaviors of CRC cells and promoted the anti-tumor immunity in CRC. Consistently, it has been revealed that...
SPOP serves as a tumor repressor gene in gastric, colorectal, and prostate cancers [35]. Importantly, a publication has reported that the loss-of-function mutation in SPOP compromises ubiquitination-mediated PD-L1 degradation, thus increasing PD-L1 level and reducing the number of tumor-infiltrating lymphocytes in mouse tumors and in clinical prostate cancer specimens [36].

In conclusion, we demonstrated that the elevation of CRCSC-exosomal miR-17-5p inhibits SPOP to facilitate the growth and restrain the anti-tumor immunity in CRC cells via promoting PD-L1. This study may provide a novel insight into the role of exosomal miR-17-5p in CRC progression. However, more efforts are still needed to reveal the underlying molecular mechanisms.

MATERIALS AND METHODS

Study subjects
Seventy CRC patients (26 males and 44 females, aged from 24 years to 84 years; median age: 48 years old) from Shengjing Hospital of China Medical University were recruited. No patients had received any treatment before surgery. Tumor tissues of these patients were collected as the experimental group; while normal tissues 5 cm away from CRC tissues were taken as the control group.

Cell culture
CRC cell line HCT116 (China Center for Type Culture Collection, Shanghai, China) was incubated with Roswell Park Memorial Institute (RPMI)-1640 medium (Corning Inc., NY, USA) containing 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin.

CRC stem cell sorting
HCT116 cells were cultured in a sphere formation medium (SFM) as previously described [37]. The cultured cells (1 x 10^7 cells) were resuspended and incubated with anti-human CD133 (1:10, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and anti-CD44 (1:50, eBioscience Inc., CA, USA) for 20 min, and then were analyzed using a flow cytometer. Cells with purity >80% after sorting were used for further analysis. The FACSaria system (Becton-Dickinson, NJ, USA) was used for cell sorting and the analysis was performed using FlowJo software. The sorted CD133^+CD44^+ HCT116 cells were cultured in SFM.
Cell transfection

Cells were seeded into 6-well plates 24 h before transfection. When the cell confluence reached about 50%, CD133+CD44+ HCT116 cells were transfected with miR-17-5p-negative control (NC), miR-17-5p mimic, or miR-17-5p inhibitor (RiboBio Co., Ltd., Guangdong, China) using Liposome 3000 (Thermo Fisher Scientific, MA, USA). pcDNA-NC and pcDNA-SPOP plasmids constructed by GenePharma (Shanghai, China) were transfected into HCT116 cells. The medium was replaced 6 h later. After 48-h transfection, cells were collected for follow-up experiments.

Isolation and identification of CRCSC-exos

CD133+CD44+ HCT116 cells were centrifuged at 300 × g for 10 min to remove dead and floating cells, and then the cells were centrifuged at 2000 × g for 10 min to remove cell debris. The supernatant was used to extract the exosomes through the exosome extraction kits (BestBio, Nanjing, China) transfected into HCT116 cells. The medium was replaced 6 h later. After 48-h transfection, cells were collected for follow-up experiments.

Exosome uptake

PKH26 red fluorescent cell junction Kit (Sigma-Aldrich, CA, USA) was used for cell tracking. The exosomes were resuspended and stained with PKH26 dye solution for 5 min. The same volume of dye solution was added to exosomes immediately and incubated for 5 min. Then, 10% bovine serum albumin (BSA, 600 μL) prepared in Dulbecco’s pluripotent stem cells was added to the exosome for 1-min staining. The 20 μg/mL PKH26-labeled exosomes were incubated with HCT116 cells overnight and the Zeiss LSM880 laser scanning confocal system (Carl Zeiss, Oberkochen, Germany) was used for imaging. The image was processed by ZEN 2009 Light Edition software (Carl Zeiss).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

TRizol kits (Thermofisher) were used to extract total RNA in tissues and cells, and the mRNA and miRNA were reversely transcribed into cDNA using Prime Script RT Master Mix Kit (TaKaRa, Dalian, China) and Mir-X miRNA First-Strand Synthesis Kit (Takara, Dalian, China). The PCR was performed using the Prime Script RT Master Mix Kit (TaKaRa, Dalian, China). U6 and
glyceraldehyde phosphate dehydrogenase (GAPDH) as the endogenous references. Each PCR product was repeated three times. Data were analyzed using the 2\(^{-\Delta\Delta Ct}\) method \[38\] and primers (Sangon Biotechnology Co., Ltd., Shanghai, China) are shown in Supplementary Table 1.

**Western blot analysis**
Total protein was extracted from tissues and cells. Protein concentrations were measured using a commercial bicinchoninic acid kit (Pierce, Rockford, IL, USA). The extracted protein was added to the loading buffer and boiled at 95 °C for 10 min. There were 30 \(\mu\)g samples in each well. The protein was separated by 10% polyacrylamide gel electrophoresis, the electrophoretic voltage was turned from 80 to 120 V and subjected to wet transfer. The voltage of the transfer membrane was 100 MV, and the time was set for 45–70 min. The protein was removed to polyvinylidene fluoride membrane, blocked with 5% bovine serum albumin for 1 h, and added with primary antibodies GAPDH (1:1000, Sungene, Shanghai, China), SPOP (1:1000, Cell Signaling Technology [CST], MA, USA), PD-L1 (1:1000, ABclonal, Wuhan, China) and CD81 (1:1000, ABclonal) at 4 °C overnight. Thereafter, the proteins were rinsed with Tris-buffered saline with Tween 20 for 3 times/5 min, incubated with appropriate secondary antibody (CST, 1:2000) for 1 h, and developed with chemiluminescence reagent. Then, proteins were observed using the ECL Western Blotting Detection system (Millipore Inc., MA, USA). The experiment was repeated 3 times and the average was calculated.

**Colony formation assay**
One hundred cells were seeded and the medium was discarded when the colonies could be observed. Colonies were fixed in formaldehyde, stained with 10% Giemsa (Sigma), and counted using a microscope (Leica DMI, Leica Microsystems Inc., IL, USA).

**Cell counting kit-8 (CCK-8) assay**
The CCK-8 assay kit (DOJINDO, Shanghai, China) was adopted to test the cell proliferative ability based on the manufacturer’s instructions. Cells were seeded at the 96-well plate at 4000 cells/well and the cell viability at 0, 24, and 48 h was detected using CCK-8 assay based on the manufacturer’s information. The proliferative rate was measured by assessing the absorbance of the cells at 450 nm using a microplate reader (Tecan Group, Ltd., Mannedorf, Switzerland) \[39\].

**Flow cytometry**
The apoptosis rate was examined using the Annexin V-FITC Apoptosis Detection Kit (BioLegend, San Diego, CA, USA). The cells were harvested and resuspended in loading buffer (1 \(\times\) 10^6 cells/mL). The cell suspension was then added with 5 \(\mu\)L PI and 5 \(\mu\)L Annexin V-FITC before incubation in a dark chamber for 15 min. The stained cells were analyzed using a BD FACSCalibur cell analyzer (BD Biosciences, NJ, USA). All data were analyzed using the CellQuest software (BD Biosciences) \[39\].
Transwell assay

The migration and invasion of cells were assessed using Transwell assay referring to a publication [40]. Specifically, 1 × 10^5 cells were resuspended in a serum-free medium and plated into the upper transwell chamber (Corning, NY, USA) and cultured in FBS-free medium. A complete growth medium with 10% FBS was added to the lower chamber. After 24 h, the cells remaining on the upper surface of the membrane were discarded with a cotton swab. The invaded and migrated cells were then fixed with 4% paraformaldehyde and stained with 0.5% crystal violet. Thereafter, the cells were imaged using an inverted optical microscope (Olympus Corporation, Tokyo, Japan) and cells in six random visual fields were counted. The experimental procedure of invasion determination was the same as that of the migration test, except that Matrigel (BD Biosciences) was precoated in the upper chamber of transwell during invasion determination [41].

Establishment of the xenograft mouse model

BALB/C mice aged 5-8 w were injected with 0.5 mL HCT116 cell suspension (~1 × 10^6 cells) at the subcapsular region of the cecum, and then, respectively, treated after 1 week and divided into 5 groups (n = 5): the PBS (injection of PBS), Exo (injection of CRCSC-exos), miR-17-5p-NC-Exo (injection of CRCSC-exos transmitting miR-17-5p NC), miR-17-5p mimic-Exo (injection of CRCSC-exos transmitting miR-17-5p mimic) and miR-17-5p inhibitor-Exo (injection of CRCSC-exos transmitting miR-17-5p inhibitor) groups.

The length and width of tumors were measured using a vernier caliper every 7 days. After the experiment, mice were anesthetized by injection of 0.3% pentobarbital sodium and euthanized with neck dislocation. The xenografts were resected, photographed, and weighed [42].

Immunohistochemistry

Tumor tissues were fixed with 10% formalin and embedded with paraffin and sliced into 5 µm sections. Sections were then deparaffinized at 60 °C for 1 h and then subjected to xylene, ethanol gradient (100–70%), and water. After incubation with 3% hydrogen peroxide for 30 min, sections were boiled in citrate buffer for 20 min. After being sealed with 5% goat serum, the sections were subjected to incubation with primary antibodies (all from Cell Signaling Technology) anti-CD4 (1:100), anti-CD8α (1:400), anti-SPOP (1:200), anti-PD-L1 (1:200) and then incubated with secondary antibody and SignalStain Boost immunohistochemistry Detection Reagent. Afterward, the sections were subjected to incubation with 3,3'-diaminobenzidine (Vector Laboratories 0), counterstaining with W. Sun et al.
hematoxylin, dehydration with the ethanol gradient (70%–100%) and xylene, and mounting with Permount. The section images were captured through the 3DHitech P250 High Capacity Slide Scanner. The quantification data were collected. Secondary antibodies without primary antibodies were set as NC [43].

**Hematoxylin–eosin (HE) staining**

Tumor tissues were collected, fixed in 10% neutral buffered formalin, dehydrated in an alcohol gradient, embedded with paraffin, and cut into 3 μm sections, and then stained with HE. Briefly, the paraffin sections were dewaxed with water and subjected to 1-min staining with hematoxylin, 5-s differentiation, and 2-min staining with eosin. Sections were removed quickly once they became pink. The sections were rinsed with tap water to make the sections indicate obvious blue. The cell nuclei were overtly observed, dehydrated, cleared, and the slides were fixed with neutral gum.

**Enzyme-linked immunosorbent assay**

The serum of mice was collected from mice 72 h after injection of exosomes. According to the manufacturer’s instructions of the ELISA kit (ExCell Bio, Shanghai, China), the corresponding reagents and samples were added to assess the absorbance value (A450) of each well. TNF-α, IL-2, IL-10, and TGF-β standard curves (γ = 0.9990) were plotted to measure the contents of T cell cytokines in mouse serum [42].

**Dual-luciferase reporter gene assay**

Binding sites between miR-17-5p and SPOP were predicted at a bioinformatics website. The 3′-UTR sequence of wild-type (WT) or
mutant-type (Mut) SPOP was inserted into the pmirGLO Dual-Luciferase vector (Promega, Madison, WI, USA). The SPOP-wild type (wt) and SPOP-mutant type (mut) were established and respectively co-transfected with miR-17-5p-mimic and miR-17-5p-NC into HCT116 cells for 48 h. Cells were lysed and the luciferase activity was assessed.

RNA immunoprecipitation (RIP) assay

The RIP assay was performed using Magna RNA kits (Millipore). HCT116 cells were lysed using RIP buffer solution and incubated with RIP buffer solution containing magnetic beads conjugated with Ago2 (1:1000, Abcam Inc., MA, USA) and immunoglobulin G (IgG, 1:200, Santa Cruz Biotechnology, CA, USA).

Statistical analysis

All data analyses were conducted using the SPSS 21.0 software (IBM Corp. Armonk, NY, USA). The measurement data were expressed as mean ± standard deviation. The t test was performed for comparisons between two groups and analysis of variance was used for comparisons among multiple groups, followed by Tukey’s post hoc test. P value <0.05 was indicative of a statistically significant difference.

DATA AVAILABILITY

The original contributions presented in the study are included in the article/Supplementary Material, and further inquiries can be directed to the corresponding author.
40. Fu Y, Lin L, Xia L. MiR-107 function as a tumor suppressor gene in colorectal cancer by targeting transferrin receptor 1. Cell Mol Biol Lett. 2019;24:31.
41. Dai J, Wang B, Zhao Y, Zuo X, Cui H, Chen X, et al. Long noncoding RNA LINC01426 sequesters microRNA-519d-5p to promote non-small cell lung cancer progression by increasing ETS1 expression. Cancer Manag Res. 2020;12:12697–708.
42. Tao Z, Xu S, Ruan H, Wang T, Song W, Qian L, et al. MiR-195/-16 family enhances radiotherapy via T cell activation in the tumor microenvironment by blocking the PD-L1 immune checkpoint. Cell Physiol Biochem. 2018;48:801–14.
43. Selvanesan BC, Meena K, Beck A, Meheus L, Lara O, Rooman I, et al. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice. J Immunother Cancer. 2020;8:e001250.

AUTHOR CONTRIBUTIONS
BL contributed to study design; WS, JC, YG, and JW contributed to experimental studies; WS, YY, and BH contributed to data analysis; BW contributed to manuscript editing. All authors read and approved the final manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
Written informed consent was acquired from all patients before this study. The protocol of this study was confirmed by the Ethics Committee of Shengjing Hospital of China Medical University. The protocol of animal experiments was approved by the Institutional Animal Care and Use Committee of Shengjing Hospital of China Medical University.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-022-00919-4.
Correspondence and requests for materials should be addressed to Baolin Liu.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022